<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909645</url>
  </required_header>
  <id_info>
    <org_study_id>2104-037-1209</org_study_id>
    <nct_id>NCT04909645</nct_id>
  </id_info>
  <brief_title>A Comparison of Invasive and Non-invasive Measurement of CI and SVR in Liver Transplantation</brief_title>
  <official_title>A Comparison of Invasive and Non-invasive Measurement of Cardiac Index and Systemic Vascular Resistance in Living Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who are scheduled to receive living donor liver transplantation will be monitored&#xD;
      with a radial and femoral arterial line. A pulmonary artery catheter will also be placed and&#xD;
      central venous pressure, cardiac index, and cardiac output will also be monitored.&#xD;
      Simultaneously, on the middle finger of the hand where the radial artery is monitored,&#xD;
      Clearsight (Edwards Lifesciences, Irvine, CA), a finger cuff, is placed and noninvasive blood&#xD;
      pressure, cardiac output, cardiac index are measured. Using the VitalDB program, the&#xD;
      parameters measured with the invasive methods and the parameters obtained by the noninvasive&#xD;
      method are compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In many end stage liver disease patients, cardiac output (CO) is increased and systemic&#xD;
      vascular resistance (SVR) is decreased. During liver transplantation it is common to see&#xD;
      hemodynamic instability due to massive blood loss and clamping of the major vessels. As a&#xD;
      result invasive monitoring via a pulmonary catheter is usually done to continuously monitor&#xD;
      the CO and SVR. However, because of its invasiveness, complications such as pulmonary artery&#xD;
      rupture and ventricular arrhythmia can occur.&#xD;
&#xD;
      Clearsight (Edwards Lifesciences, Irvine, CA) is a noninvasive technique using a finger cuff&#xD;
      to measure not only blood pressure but also CO and cardiac index (CI).&#xD;
&#xD;
      There have been previous reports on the correlation of this noninvasive method in other&#xD;
      patient populations but no studies have been done in liver recipients. Also no studies have&#xD;
      been done comparing SVR.&#xD;
&#xD;
      Patients presenting for living donor liver transplantation are anesthetized according to the&#xD;
      SNUH protocol. Right radial and femoral arterial lines are placed. A central catheter is&#xD;
      placed in the right jugular vein and a pulmonary artery catheter (Swan-Ganz CCOmbo CCO/SvO2™;&#xD;
      Edward Lifesciences LLC, Irvine, CA, USA) is placed. This is connected to the Vigilance™&#xD;
      hemodynamic monitor (Edwards Lifesciences) and central venous pressure (CVP), CO, CI are&#xD;
      monitored and SVR is calculated by the following equation: SVR=(Mean arterial&#xD;
      pressure-CVP)*80/CO. The Clearsight system is connected after the finger cuff is placed on&#xD;
      the middle finger of the right hand. Blood pressure, CO, CI are measured and SVR is&#xD;
      calculated.&#xD;
&#xD;
      The variables are compared in the following phases:&#xD;
&#xD;
      Phase 1 (preanhepatic): induction - recipient hepatectomy Phase 2 (anhepatic1): recipient&#xD;
      hepatectomy - Inferior Vena Cava (IVC) clamping Phase 3 (anhepatic2): IVC clamping -&#xD;
      reperfusion Phase 4 (reperfusion): reperfusion - 5mins postreperfusion Phase 5 (neohepatic):&#xD;
      5 mins postreperfusion - end of surgery&#xD;
&#xD;
      The investigators hypothesize that the noninvasive hemodynamic monitoring method by the&#xD;
      Clearsight will be able to replace the invasive monitoring by the pulmonary artery catheter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for cardiac index</measure>
    <time_frame>Phase 1 (preanhepatic): 60 minutes after the anesthetic induction</time_frame>
    <description>cardiac index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systemic vascular resistance</measure>
    <time_frame>Phase 1 (preanhepatic): 60 minutes after the anesthetic induction</time_frame>
    <description>systemic vascular resistance measured by the following equation: SVR=(Mean arterial pressure-central venous pressure)*80/cardiac output.&#xD;
Femoral MAP is used for the invasive measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for cardiac index</measure>
    <time_frame>Phase 2 (anhepatic 1): 10 minutes after recipient hepatectomy is complete</time_frame>
    <description>cardiac index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systemic vascular resistance</measure>
    <time_frame>Phase 2 (anhepatic 1): 10 minutes after recipient hepatectomy is complete</time_frame>
    <description>systemic vascular resistance measured by the following equation: SVR=(Mean arterial pressure-central venous pressure)*80/cardiac output.&#xD;
Femoral MAP is used for the invasive measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for cardiac index</measure>
    <time_frame>Phase 3 (anhepatic 2): 10 minutes after IVC clamping</time_frame>
    <description>cardiac index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systemic vascular resistance</measure>
    <time_frame>Phase 3 (anhepatic 2): 10 minutes after IVC clamping</time_frame>
    <description>systemic vascular resistance measured by the following equation: SVR=(Mean arterial pressure-central venous pressure)*80/cardiac output.&#xD;
Femoral MAP is used for the invasive measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for cardiac index</measure>
    <time_frame>Phase 4 (reperfusion): 5 minutes after reperfusion</time_frame>
    <description>cardiac index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systemic vascular resistance</measure>
    <time_frame>Phase 4 (reperfusion): 5 minutes after reperfusion</time_frame>
    <description>systemic vascular resistance measured by the following equation: SVR=(Mean arterial pressure-central venous pressure)*80/cardiac output.&#xD;
Femoral MAP is used for the invasive measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for cardiac index</measure>
    <time_frame>Phase 5(neohepatic): 1 hour after reperfusion</time_frame>
    <description>cardiac index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systemic vascular resistance</measure>
    <time_frame>Phase 5(neohepatic): 1 hour after reperfusion</time_frame>
    <description>systemic vascular resistance measured by the following equation: SVR=(Mean arterial pressure-central venous pressure)*80/cardiac output.&#xD;
Femoral MAP is used for the invasive measurement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systolic and diastolic blood pressure</measure>
    <time_frame>Phase 1 (preanhepatic): 60 minutes after the anesthetic induction</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systolic and diastolic blood pressure</measure>
    <time_frame>Phase 2 (anhepatic 1): 10 minutes after recipient hepatectomy is complete</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systolic and diastolic blood pressure</measure>
    <time_frame>Phase 3 (anhepatic 2): 10 minutes after IVC clamping</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systolic and diastolic blood pressure</measure>
    <time_frame>Phase 4 (reperfusion): 5 minutes after reperfusion</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of invasive and non-invasive measurement for systolic and diastolic blood pressure</measure>
    <time_frame>Phase 5(neohepatic): 1 hour after reperfusion</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Living Donor Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Clearsight (finger cuff)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Clearsight (finger cuff)</intervention_name>
    <description>Clearsight (Edwards Lifesciences, Irvine, CA), a noninvasive technique, uses a finger cuff to measure blood pressure, cardiac output (CO) and cardiac index. Systemic vascular resistance (SVR) is calculated by the following equation: SVR=(Mean arterial pressure-Central venous pressure)*80/CO.</description>
    <arm_group_label>Clearsight (finger cuff)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  routine living donor liver transplantation recipients needing pulmonary artery&#xD;
             catheterization who have been informed and given consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with atrial fibrillation&#xD;
&#xD;
          -  Contraindications to pulmonary artery catheterization or needing attention to&#xD;
             insertion of pulmonary artery catheter: right-sided endocarditis, tumors, right sided&#xD;
             valvular disease, left bundle branch block&#xD;
&#xD;
          -  Patients with obstructive vascular disease in the upper extremities, anatomical&#xD;
             deformities in the upper extremities, Raynaud syndrome, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong Mi Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seong Mi Yang</last_name>
    <phone>+82-10-7300-6282</phone>
    <email>seongmi.yang@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Mi Yang</last_name>
      <phone>82-10-7300-6282</phone>
      <email>seongmi.yang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>De Wolf AM. 6/2/06 Perioperative assessment of the cardiovascular system in ESLD and transplantation. Int Anesthesiol Clin. 2006 Fall;44(4):59-78. Review.</citation>
    <PMID>17033479</PMID>
  </reference>
  <reference>
    <citation>Rudnick MR, Marchi LD, Plotkin JS. Hemodynamic monitoring during liver transplantation: A state of the art review. World J Hepatol. 2015 Jun 8;7(10):1302-11. doi: 10.4254/wjh.v7.i10.1302. Review.</citation>
    <PMID>26052376</PMID>
  </reference>
  <reference>
    <citation>Evans DC, Doraiswamy VA, Prosciak MP, Silviera M, Seamon MJ, Rodriguez Funes V, Cipolla J, Wang CF, Kavuturu S, Torigian DA, Cook CH, Lindsey DE, Steinberg SM, Stawicki SP. Complications associated with pulmonary artery catheters: a comprehensive clinical review. Scand J Surg. 2009;98(4):199-208. Review.</citation>
    <PMID>20218415</PMID>
  </reference>
  <reference>
    <citation>Saugel B, Hoppe P, Nicklas JY, Kouz K, Körner A, Hempel JC, Vos JJ, Schön G, Scheeren TWL. Continuous noninvasive pulse wave analysis using finger cuff technologies for arterial blood pressure and cardiac output monitoring in perioperative and intensive care medicine: a systematic review and meta-analysis. Br J Anaesth. 2020 Jul;125(1):25-37. doi: 10.1016/j.bja.2020.03.013. Epub 2020 May 29.</citation>
    <PMID>32475686</PMID>
  </reference>
  <reference>
    <citation>Saugel B, Cecconi M, Wagner JY, Reuter DA. Noninvasive continuous cardiac output monitoring in perioperative and intensive care medicine. Br J Anaesth. 2015 Apr;114(4):562-75. doi: 10.1093/bja/aeu447. Epub 2015 Jan 16. Review.</citation>
    <PMID>25596280</PMID>
  </reference>
  <reference>
    <citation>Kim SH, Lilot M, Sidhu KS, Rinehart J, Yu Z, Canales C, Cannesson M. Accuracy and precision of continuous noninvasive arterial pressure monitoring compared with invasive arterial pressure: a systematic review and meta-analysis. Anesthesiology. 2014 May;120(5):1080-97. doi: 10.1097/ALN.0000000000000226. Review.</citation>
    <PMID>24637618</PMID>
  </reference>
  <reference>
    <citation>Al-Hamoudi WK. Cardiovascular changes in cirrhosis: pathogenesis and clinical implications. Saudi J Gastroenterol. 2010 Jul-Sep;16(3):145-53. doi: 10.4103/1319-3767.65181. Review.</citation>
    <PMID>20616408</PMID>
  </reference>
  <reference>
    <citation>Kanazawa H, Maeda T, Miyazaki E, Hotta N, Ito S, Ohnishi Y. Accuracy and Trending Ability of Blood Pressure and Cardiac Index Measured by ClearSight System in Patients With Reduced Ejection Fraction. J Cardiothorac Vasc Anesth. 2020 Dec;34(12):3293-3299. doi: 10.1053/j.jvca.2020.03.045. Epub 2020 Apr 20.</citation>
    <PMID>32404245</PMID>
  </reference>
  <reference>
    <citation>Sumiyoshi M, Maeda T, Miyazaki E, Hotta N, Sato H, Hamaguchi E, Kanazawa H, Ohnishi Y, Kamei M. Accuracy of the ClearSight™ system in patients undergoing abdominal aortic aneurysm surgery. J Anesth. 2019 Jun;33(3):364-371. doi: 10.1007/s00540-019-02632-6. Epub 2019 Mar 23.</citation>
    <PMID>30904953</PMID>
  </reference>
  <reference>
    <citation>Lee HC, Jung CW. Vital Recorder-a free research tool for automatic recording of high-resolution time-synchronised physiological data from multiple anaesthesia devices. Sci Rep. 2018 Jan 24;8(1):1527. doi: 10.1038/s41598-018-20062-4.</citation>
    <PMID>29367620</PMID>
  </reference>
  <reference>
    <citation>Critchley LA, Critchley JA. A meta-analysis of studies using bias and precision statistics to compare cardiac output measurement techniques. J Clin Monit Comput. 1999 Feb;15(2):85-91.</citation>
    <PMID>12578081</PMID>
  </reference>
  <reference>
    <citation>Suehiro K, Tanaka K, Funao T, Matsuura T, Mori T, Nishikawa K. Systemic vascular resistance has an impact on the reliability of the Vigileo-FloTrac system in measuring cardiac output and tracking cardiac output changes. Br J Anaesth. 2013 Aug;111(2):170-7. doi: 10.1093/bja/aet022. Epub 2013 Mar 10.</citation>
    <PMID>23479677</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Seong Mi Yang</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>finger cuff</keyword>
  <keyword>systemic vascular resistance</keyword>
  <keyword>cardiac index</keyword>
  <keyword>noninvasive monitoring</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

